x
Filter:
Filters applied
- Commentary
- Alexandre, MarinaRemove Alexandre, Marina filter
- confidence intervalRemove confidence interval filter
Publication Date
Please choose a date range between 2018 and 2018.
Author
- Avenel-Audran, Martine2
- Benichou, Jacques2
- Bernard, Philippe2
- D'Incan, Michel2
- Dereure, Olivier2
- Abasq, Claire1
- Bagot, Martine1
- Bara, Corina1
- Bedane, Christophe1
- Bernier, Claire1
- Beylot-Barry, Marie1
- Borradori, Luca1
- Bouaziz, Jean David1
- Boulard, Claire1
- Bourgault-Villada, Isabelle1
- Bouyeure, Anne Charlotte1
- Camaioni, Diana B1
- Caux, Frederic1
- Chaby, Guillaume1
- Collet, Evelyne1
- Debarbieux, Sebastien1
- Delaporte, Emmanuel1
- Della Torre, Rocco1
- Didona, Biago1
Keyword
- CI2
- ABSIS1
- Autoimmune Bullous Skin Disorder Intensity Score1
- BP1
- bullous pemphigoid1
- Dermatology Quality of Life Index1
- dipeptidyl peptidase-41
- DLQI1
- DPP-41
- Echantillon Généraliste des Bénéficiaires (database of the National French Health Insurance Agency)1
- EGB1
- ICC1
- interquartile range1
- intraclass correlation coefficient1
- IQR1
- M1
- month1
- PDAI1
- Pemphigus Disease Area Index1
- pemphigus foliaceus1
- PF1
- PGA1
- Physician Global Assessment1
- PV1
Pemphigus & Pemphigoid
2 Results
- Original Article Clinical Research: EpidemiologyOpen Archive
Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population
Journal of Investigative DermatologyVol. 139Issue 4p835–841Published online: December 10, 2018- Marthe Plaquevent
- Florence Tétart
- Laurence Fardet
- Saskia Ingen-Housz-Oro
- Laurence Valeyrie-Allanore
- Philippe Bernard
- and others
Cited in Scopus: 52Dipeptidyl peptidase-4 inhibitors have been suspected to induce bullous pemphigoid (BP). The objective of this study was to compare the observed frequency of gliptin intake in a large sample of 1,787 BP patients diagnosed between 2012 and 2015 in France, with the expected frequency after indirect age standardization on 225,412 individuals extracted from the database of the National Healthcare Insurance Agency. The secondary objective was to assess the clinical characteristics and the course of gliptin-associated BP, depending on whether gliptin was continued or stopped. - ReviewOpen Archive
Large International Validation of ABSIS and PDAI Pemphigus Severity Scores
Journal of Investigative DermatologyVol. 139Issue 1p31–37Published online: October 6, 2018- Vivien Hébert
- Claire Boulard
- Estelle Houivet
- Sophie Duvert Lehembre
- Luca Borradori
- Rocco Della Torre
- and others
Cited in Scopus: 41The Pemphigus Disease Area Index (PDAI) and Autoimmune Bullous Skin Disorder Intensity-Score (ABSIS) scores have been proposed to provide an objective measure of pemphigus activity. These scores have been evaluated only on already treated patients mainly with mild to moderate activity. The objective was to assess the interrater reliability of ABSIS and PDAI scores and their correlation with other severity markers in a large international study. Consecutive patients with newly diagnosed pemphigus were enrolled in 31 centers.